Table 1 Characteristics of the 14 eligible studies for meta-analysis
Studies | Year of publication | Country | Age | Male (%) | No. of patients | Echocardiographic data | ||||
|---|---|---|---|---|---|---|---|---|---|---|
T2* ≥ 20 | T2* < 20 | GLS | LVEF | |||||||
T2* ≥ 20 | T2* < 20 | T2* ≥ 20 | T2* < 20 | |||||||
Pizzino et al. [21] | 2017 | Italy | 37.4 ± 10 | 53% | 22 | 6 | 21.3 ± 2.7 | 18.3 ± 2 | 60.2 ± 4.8 | 58 ± 2.4 |
Parsaee et al. [15] | 2018 | Iran | 30.79 ± 9.37 | 45% | 81 | 41 | -19 (-18 to -20) | -17 (-19 to -16) | 63 (59–68) | 58 (53–63) |
Abtahi et al. [22] | 2019 | Iran | 23.7 ± 5 | 56% | 28 | 22 | 21.55 ± 2.68 | 17.64 ± 2.56 | 58.5 ± 5 | 59.32 ± 4.9 |
Ari et al. [16] | 2017 | Turkey | 13.3 ± 16.1 | 50% | 20 | 10 | -23.10 ± 2.20 | -19.70 ± 3.10 | 68.3 ± 3.5 | |
Rezaeian et al. [17] | 2020 | Iran | 24.66 ± 6.23 | 57.1% | 25 | 66 | -13.81 ± 3.25 | -12.9 ± 4.18 | 52.0 ± 12.4 | |
Hanneman et al. [23] | 2016 | Canada | 34.6 ± 9.5 | 53% | 11 | 19 | -18.8 ± 3.5 | -19.4 ± 1.8 | 58.5 ± 5.5 | 60.4 ± 4.4 |
Parsaee et al. [24] | 2019 | Iran | 31.96 ± 7.5 | 44.4% | 25 | 20 | -22.36 ± 2.34 | -21.73 ± 1.71 | - | |
Garceau et al. [25] | 2011 | Canada | 34.4 ± 11 | 46.6% | 23 | 22 | -20 ± 2 | -16 ± 3 | 64 ± 5 | 59 ± 7 |
Nadar et al. [26] | 2020 | Oman | 26.3 ± 6.1 | 42.8% | 61 | 23 | -19.2 ± 2.8 | -18.6 ± 2.4 | 59.5 ± 6.7 | 60.4 ± 5.2 |
El-Shanshory et al. [4] | 2020 | Egypt | 10.9 ± 3.7 | 66.6% | 68 | 32 | -21.23 ± 2.68 | -21.375 ± 2.06 | 54.88 ± 12.47 | 49.88 ± 14.04 |
Djer et al. [28] | 2020 | Indonesia | 13–41 | 50% | 16 | 14 | - | 65.6 (60.6–75.5) | 64.8 (60.5–75) | |
Barzin et al. [29] | 2012 | Iran | 23.5 (15–37) | 48.4% | 16 | 14 | - | 60.3 ± 3.99 | 51.1 ± 4.39 | |
Poorzand et al. [30] | 2019 | Iran | 23.51 ± 6.2 | 52.35% | 30 | 14 | -20.28 ± 1.67 | -18.23 ± 3.41 | 58.6 ± 2.87 | 56.05 ± 8.8 |
Odoardo et al. [31] | 2017 | Italy | 36.6 ± 7 | 38.2% | 34 | 21 | -19.2 ± 3 | -18.8 ± 2.6 | 61 ± 5.3 | 60.6 ± 6.2 |